PolicyBrief
H.R. 8000
119th CongressMar 19th 2026
END 7-OH Act
IN COMMITTEE

The END 7-OH Act classifies synthetic 7-hydroxymitragynine as a Schedule I controlled substance while exempting the substance when naturally occurring in kratom.

Gus Bilirakis
R

Gus Bilirakis

Representative

FL-12

LEGISLATION

END 7-OH Act Bans Synthetic Kratom Compounds: Natural Leaf Stays Legal While Lab-Made Versions Hit Schedule I List

The END 7-OH Act moves to place synthetic 7-hydroxymitragynine—a potent chemical often derived from or related to the kratom plant—into the federal government’s most restrictive category: Schedule I. By adding this substance to the Controlled Substances Act under Section 2, the bill effectively bans the manufacture, sale, and possession of synthetic versions of the compound. However, the bill includes a critical carve-out: it explicitly states that the natural 7-hydroxymitragynine found within the Mitragyna speciosa (kratom) plant itself is not affected. This means while the lab-made concentrates are on the chopping block, the raw plant remains in its current legal status.

The Lab vs. The Leaf

This bill creates a sharp legal divide between what grows in the ground and what is cooked in a lab. For a small business owner selling kratom powders or teas, the 'natural' exemption in Section 2 means their primary inventory stays off the federal controlled substances list for now. On the flip side, a manufacturer producing high-potency synthetic shots or tablets that rely on 'synthetic equivalents' of 7-hydroxymitragynine would see their entire product line become illegal overnight. This is a massive shift for the supplement industry, targeting the 'gas station' products that have drawn heat for their concentrated potency while sparing the traditional plant-based market.

Defining 'Synthetic' in the Real World

The biggest hurdle here is the bill’s use of the term 'synthetic equivalents' without providing a strict scientific roadmap for testing. If you are a consumer using these products for wellness, you might find your go-to brand suddenly pulled from the shelves because the manufacturer can't prove their extraction process doesn't cross the line into 'synthetic' territory. Because Schedule I classification is reserved for drugs with 'no currently accepted medical use,' this change also cuts off most private research into the compound. It creates a high-stakes environment where the difference between a legal herbal product and a federal felony depends entirely on a laboratory's definition of where nature ends and chemistry begins.